Teva Rises to Five-Month High on U.S.-Traded Shares Advance

Teva Pharmaceutical Industries Ltd. (TEVA), the world’s largest maker of generic drugs, climbed to the highest level in almost five months following an increase in its U.S.-traded stock.

The shares in the Petach-Tikva, Israel-based company rose to the highest level since July 20, gaining 2.8 percent to 162.90 shekels, or the equivalent of $42.89, at the 4:30 p.m. close in Tel Aviv. Teva’s U.S.-traded shares closed at $42.72 on Dec. 16.

Teva has declined 12 percent in Tel Aviv this year.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.